HALIFAX, Jan. 3 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid
diagnostic solutions, announced today that it has been granted a patent for
the HCV Mosaic Antigen by the European Patent Office. This is the company's
first major patent on its rapid diagnostic technology in Europe, and paves the
way for the world's first combination HIV and Hepatitis C instant rapid test.
Hepatitis C (HCV) impacts over 170 million people worldwide according to
the World Health Organization, which also indicates over 40% of individuals
with HIV are co-infected with HCV. A combination rapid HIV/HCV test can play a
critical role in patient outcomes.
Patent No. EP 1328 811 B1 will ensure that MedMira's rapid HCV diagnostic
technology is protected as it is brought to market in Europe. The patented
technology is a key component in MedMira's rapid HCV tests and HIV/HCV
combination tests slated for market entry in 2007.
"We are very pleased to receive this patent for our groundbreaking
technology," said Hermes Chan, president and COO of MedMira, and principal
inventor of the HCV Mosaic Antigen. "Considerable R&D efforts were dedicated
to developing this technology in the past years. Protecting this valuable
diagnostic solution through the patent process was an important step in
bringing the complete line of rapid HCV diagnostic products to the European
The HCV Mosaic Antigen is a highly immunoreactive mosaic antigen
composition containing a plurality of different antigenic peptides encoded
from the core region of the HCV genome. The granted patent also describes a
test kit utilizing the antigen, and a method for its use for the purpose of
detecting antibodies to HCV in a test sample.
MedMira is the leading global manufacturer and marketer of in vitro
flow-through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter
(OTC) product, is available in pharmacies throughout Hong Kong and Macao
Special Administrative Regions, in the People's Republic of China.
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.